Comparison of Zidovudine and Tenofovir Based Regimens With Regard to Health-Related Quality of Life and Prevalence of Symptoms in HIV Patients in a Kenyan Referral Hospital

Etenyi, Jilian O, Okalebo, Faith A, Oluka, Margaret, Sinei, Kipruto A, Osanjo, George O, Kurdi, Amanj, Meyer, Johanna C, Godman, Brian ORCID: 0000-0001-6539-6972 and Opanga, Sylvia (2018) Comparison of Zidovudine and Tenofovir Based Regimens With Regard to Health-Related Quality of Life and Prevalence of Symptoms in HIV Patients in a Kenyan Referral Hospital. FRONTIERS IN PHARMACOLOGY, 9 (OCT). 984-.

Text
PDF Etenyi et al 2018.pdf - Published version
Download (973kB)

Official URL: http://dx.doi.org/10.3389/fphar.2018.00984

Abstract

Aim: Zidovudine and tenofovir form the backbone of antiretroviral therapy in Kenya. However, their side-effects may affect the quality of life (QoL) of patients. The aim was to compare the health-related quality of life (HRQoL) of adult patients on tenofovir versus zidovudine based regimens in a referral hospital in Kenya to provide future guidance. Methods: A comparative cross sectional study among 501 adult out-patients on either tenofovir or zidovudine was undertaken in Kenyatta National Hospital between 2015 and 2016. The Medical Outcome Study HIV Health Survey (MOS-HIV) was administered along with other key aspects of treatment. Linear regression analysis was performed to identify determinants of HRQoL. Results: Patients on zidovudine had a higher Physical Health Summary Score (PHSS) and Mental Health Summary Score (MHSS) compared to those on tenofovir. The presence of any symptom of the disease and a stated inability to cope were negatively associated with PHSS, whilst having a regular source of income improved PHSS. Being on tenofovir, symptom of illness [β = -1.24; 95% CI (-2.253, -0.226)], absence of pain [β=0.413; 95% CI (0.152, 0.674)] and patient stated inability to cope with HIV [β = -1.029; 95% CI (-1.441, -0.617)] affected the MHSS. Patients on tenofovir and second line regimens had more signs and symptoms of illness. Conclusion: Participants on zidovudine based regimens showed a better performance across all aspects of HRQoL. These are considerations for the future.

Item Type:	Article
Uncontrolled Keywords:	HRQoL, MOS-HIV, side-effects, tenofovir, zidovudine, antiretroviral treatments, Kenya
Depositing User:	Symplectic Admin
Date Deposited:	14 Nov 2018 11:35
Last Modified:	19 Jan 2023 01:13
DOI:	10.3389/fphar.2018.00984
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3028617